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METABOLIC CHECKPOINTS IN CANCER CELL CYCLE 
by 
Mahesh Saqcena 
Advisor: Dr. David A. Foster 
 
Growth factors (GFs) as well as nutrient sufficiency regulate cell division in metazoans.  
The vast majority of mutations that contribute to cancer are in genes that regulate progression 
through the G1 phase of the cell cycle.  A key regulatory site in G1 is the growth factor-dependent 
Restriction Point (R), where cells get permissive signals to divide.  In the absence of GF 
instructions, cells enter the quiescent G0 state.  Despite fundamental differences between GF 
signaling and nutrient sensing, they both have been confusingly referred to as R and therefore by 
definition considered to be a singular event in G1.  Autonomy from GF signaling is one of the 
hallmarks in cancer; however, cancer cells also have metabolic rewiring enabling them to engage in 
anabolic biosynthetic pathways.  In the absence of GF instructions and nutrients, cells commonly 
undergo apoptotic cell death.  Thus, it is of importance to elucidate the differences between GF and 
nutrient deregulation in cancer to develop novel strategies in targeting tumor cell proliferation and 
survival. 
Here, we report that the GF-mediated mid-G1 restriction point (R) is distinct and 
distinguishable from a series of late-G1 metabolic checkpoints mediated by essential amino acids, 
conditionally essential amino acid – glutamine, and mTOR – the mammalian target of rapamycin.  
Our data indicate that the arrest sites mediated by various blocking conditions are in the order of  
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GF  EAA  Q  mTOR.  We temporally mapped the EAA and glutamine checkpoints at 12 hr 
from G0 and mTOR mediated arrest occurring at 16 hr from G0.  Distinct profiles for cell cycle 
regulator expression and phosphorylation was observed when released from restriction point 
relative to the metabolic checkpoints.  These data are consistent with a mid-G1 R where cells decide 
whether they should divide, followed by late-G1 metabolic checkpoints where cells determine 
whether they have sufficient nutrients to divide.  Since mTOR inhibition using rapamycin or Torin1 
arrested the cells latest in G1, mTOR may serve as the final arbiter for nutrient sufficiency prior to 
replicating the genome.  Significantly we also observed that in addition to GF autonomy, several 
cancer cells also have dysregulated nutritional sensing, and arrest in S- and G2/M phase upon 
essential amino acid and glutamine deprivation.   We identified K-Ras mutation as the underlying 
genetic cause for this phenomenon.  We found that treating cancer cells harboring K-Ras mutation 
with aminooxyacetate (AOA) – drug that interferes with glutamine utilization – causes them to 
arrest in S- and G2/M-phase, where synthetic lethality could be created to phase-specific cytotoxic 
drugs.  Thus, besides addressing the long standing assumption of GF and nutrients regulating G1 
cell cycle progression, our work provides rationale and proof of principle for targeting metabolic 
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Mammalian Cell Cycle 
The mammalian cell cycle has been divided into four distinct phases, namely, G1 (for gap 
1), S (for synthesis of DNA), G2 (for gap 2), and M (for mitotic phase).  The vast majority of 
mutations that contribute to cancer are in genes that regulate progression through the G1 phase of 
the cell cycle (1).  A key regulatory site in G1 is the growth factor-dependent Restriction Point (R), 
originally described by Pardee (2), where cells get permissive signals to progress through G1 and 
divide.  Alternatively, in the absence of growth factor (GF), cells enter a quiescent G0 state.  This 
GF-dependent R has been mapped to a site about 3 to 4 hr post-mitosis (3).  In addition to GF 
instructions, it is widely acknowledged that nutrient availability and mTOR activity also impact on 
G1 cell cycle progression(4, 5).  It has been suggested that R in mammalian cells is analogous to 
START in yeast cell cycle.  However, yeasts are single celled and it is known that TOR-regulated 
START in yeast is a sensor of nutrient availability (6, 7).  We have hypothesized the existence of a 
distinct Cell Growth checkpoint(s) in late G1, where cells ensure the availability of adequate raw 
materials (essential amino acids, glutamine) before committing for proliferation (8).  Thus, START 
in yeast is more likely evolutionally related to the proposed Cell Growth checkpoint rather than the 
GF-mediated R. 
Despite fundamental differences between GF signaling and nutrient sensing, they both have 
been confusingly referred to as R and therefore by definition considered to be a singular event in 
G1.  Some of the reasons that suggest that R and Cell Growth checkpoints are distinct are: (i) there 
are mechanistic differences between sensing mechanisms for GF and nutrient sufficiency, (ii) 
normal non-transformed cells respond differently to GF and nutrient deprivation – for example 
arresting in a quiescent G0 state vs. induction of autophagy, respectively, (iii) cancer cells respond 
differently to GF and nutrient deprivation – for example most cancer cells exhibit autonomy from 
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growth factor signaling but are exquisitely sensitive to nutritional deprivation triggering apoptosis, 
and (iv) complementing genetic changes required for transformation are in genes that override 
restriction point and in genes that override the nutritional sensing (8). 
 
Complementing Genetic Mutations Required for Transformation 
Weinberg et al. have shown that in addition to telomerase, Ras along with SV40 large and small T 
antigens are required to transform normal human cells (9, 10).  The molecular and cell cycle targets 
of Ras and large and small T antigen implicated in G1 cell cycle progression is shown in Table 1.  
While the telomerase requirement indicated a need to acquire immortality and avoid cell 
senescence, all of the other genes have been implicated in progression through G1 (Table 1). 
 
Table 1.  Genetic requirements for the transformation of Human Cells. 
[From Foster et al. (8)] 
 (9, 10, 11) . 
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Ras pathway is activated in response growth factor signaling and mutation in the pathway is 
known to confer autonomy from GFs.  Both SV40 large and small T antigens inhibit proteins which 
are involved in G1 cell cycle progression. Thus, this suggests that dysregulating signals involved in 
progression through G1 phase of cell cycle is sufficient for transformation.  Attempting 
transformation without viral genes, Hahn et al. showed that human cells can be transformed using a 
combination of Ras, suppression of p53 and Rb, increased expression of Myc and suppression of 
PTEN expression, in addition to telomerase (11).  Thus, activation of both Ras and PI3K/mTOR 




Figure 1.  Complementary signaling pathways activated in human cancer cells. 
Two signaling pathways are shown that are commonly activated in cancer cells.  It is proposed that 
activation of these two signaling pathways promotes progression through different regulatory points 
in G1 of the cell cycle.  A) The Ras pathway involves the activation of a kinase cascade consisting 
of Raf, Mek and MAP kinase (MAPK), leading to increased expression of cyclin D and passage 
through R.  This pathway is ordinarily activated by growth factors that prevent G1 cell cycle exit to 
quiescence.       B) The mTOR pathway is complicated and has many inputs.  However, a common 
theme in this complex signaling network is that it is highly sensitive to the presence of the energy 
and nutrients needed for cell growth and leads to the activation of cyclin E and its partner kinase 






mTOR is a key sensor of nutrient availability 
In addition to the GF-mediated restriction point (R), non-transformed cells also have nutrient 
sensing checkpoints and p53-mediated G1/S checkpoint for assessing genomic integrity (Fig. 2).  
mTOR is a key sensor of nutrient availability and in addition to GF signaling is also responsive to 
energy status, glucose, amino acids, and lipid levels.  mTOR regulates the proposed cell growth 
checkpoint by suppressing TGF-β signaling, which stimulates the expression cell cycle inhibitor 
p27.  Based on the complementing genetic mutations required for tumorigenesis, there is an 




Figure 2.  Proposed G1 Cell Cycle Checkpoints. 
Two major cell cycle checkpoints in G1 are proposed: 1) The Restriction Point that monitors growth 
factor instructions and is regulated in part by cyclin D-CDK4/6; and 2) A checkpoint mediated by 
mTOR and TGF-  that monitors nutritional sufficiency and that is equivalent to START in yeast.  







Metabolic Reprogramming – The Seventh Hallmark in Cancer 
Metabolic dysregulation is an emerging hallmark in cancer (12).  Cancer cells exhibit a 
marked propensity to ferment glucose into lactate even in the presence of adequate oxygen.  This 
metabolic transformation was first described by Otto Warburg in the early 1920s – and named 
Warburg effect (13) , who postulated that defects in mitochondrial activity accounts for 
tumorigenesis.  Since then, it has become apparent that metabolic transformation is not a cause but 
rather a consequence of tumorigenesis and that cancer cells do have a functional mitochondria.  
Nonetheless, cancer cell’s “sweet tooth” (14) for glucose uptake has been exploited in FDG-PET 
scanning, a diagnostic procedure that can localize sites of tumor invasion and metastases.  Several 
oncogenes and survival signals have been shown to directly upregulate glycolytic enzymes and the 
metabolic reprogramming (15-17).  For instance, in many cancers the constitutively expressed 
transcriptional regulator hypoxia inducible factor (HIF-1) has been shown to upregulate glycolysis 
(18, 19).  Similarly, activated Akt has been shown to stimulate aerobic glycolysis in cancer cells 
(20).  The Myc oncogene can transcriptionally upregulate lactate dehydrogenase and pyruvate 
dehydrogenase kinase, both of which can shift the metabolic flux to increased lactate production 
and decreased mitochondrial respiration (21, 22).  Mutant p53 has been shown to transcriptionally 
upregulate hexokinase II and trigger the Warburg effect (23, 24).  Christofk et al. have found that 
the M2 spliced variant of pyruvate kinase (PKM2) can by itself lead to metabolic switch (25, 26).  
In addition to PKM2 isoform having lower activity than PKM1, which would redistribute the 
glucose to anabolic pathways, it was hypothesized that PKM2 promotes tumor growth and aerobic 
glycolysis by virtue of its unique interaction, amongst all PK isoforms, with tyrosine-
phosphorylated proteins, leading to its inhibition.  The “Warburged state” was reversed upon 
switching the pyruvate kinase expression to the adult, M1 isoform.  Mutations in several of the 
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citric acid cycle enzymes such as isocitrate dehydrogenase, succinate dehydrogenase, and fumarate 
hydratase have been linked to oncogenesis and/or familial paragangliomas/leiomyomas (27-31). 
 
Glutamine in Cancer Metabolism 
In the absence of glucose-derived acetyl CoA to fuel the mitochondrial citric acid cycle 
owing to aerobic glycolysis, glutamine acts as the anaplerotic precursor to generate alpha-
ketoglutarate, an intermediate in the TCA cycle.  It was reported that cancer cells convert 90% of 
glucose consumed into lactate and about 60% of glutamine consumed is also metabolized to lactate 
via malic enzyme (32).  It has also been shown that oncogene Myc can upregulate glutaminase 
activity, leading to glutamine addiction in cancer cells (33, 34).  Nicklin et al. have reported that 
glutamine uptake is followed by its rapid efflux from the cells in exchange for essential amino 
acids, and either the blockage of this exchange or glutamine withdrawal can induce autophagy (35).  
Thus, there is mounting evidence that underline the importance of glutamine in cancer cell 
metabolism.  It is hypothesized that glutamine favors proliferation by replenishing citric acid cycle 
intermediates.  Glutamine has also been implicated as a regulator of DNA and protein biosynthesis 
in solid human cancer cell lines (36).  The response of cancer cells to glutamine deprivation seems 
to depend on mutations they harbor.  For example, glutamine deprivation has been reported to cause 
apoptosis in Myc-dependent manner (37).  On the other hand, in K-Ras transformed fibroblasts, 
glutamine deprivation has been shown to induce abortive S-phase (38).  While glutamine has been 
reported to play pleiotropic roles in tumor proliferation (39, 40), the impact of glutamine 




Scope of Work 
In Chapter 2, we provide evidence indicating that R and nutritional checkpoints are distinct 
and temporally distinguishable.  We show that GF and nutritional deprivation cause G1 cell cycle 
arrest utilizing different cell cycle regulators.  Importantly, we demonstrate that in addition to GF 
autonomy, nutritional sensing is dysregulated in most cancer cells leading to override of G1 cell 
cycle arrest upon nutrient starvation.  In addition to underscoring critical differences between R and 
nutritional checkpoints, our data also suggest that metabolic deregulation in cancer provides novel 
molecular targets for therapeutic intervention. 
Extending our observation that some cancer cells have dysregulated amino acid sensing, in 
Chapter 3 we show that in cancer cells oncogenic K-Ras mutations provide G1 arrest override upon 
glutamine deprivation.  We also demonstrate that the cyclin profiles in K-Ras mutant cells that 
arrest in S- and G2/M-phase correlates with the cell cycle arrest seen in flow cytometry.  We find 
that dual inhibition of K-Ras/MAPK and PI3K/mTOR signaling pathways is required to restore G1 
arrest upon glutamine deprivation, suggesting that cross-talk and compensation between these two 
pathways provide the G1 arrest override in K-Ras mutant cancer cell lines. Importantly, we also 
demonstrate that this differential sensitivity to glutamine can be exploited in specifically targeting 





Chapter 2:  Amino acids and mTOR Mediate Distinct Metabolic Checkpoints in Mammalian 
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In multicellular organisms, cell division is regulated by growth factor signaling.  In the 
absence of growth factors, cells exit the cell cycle at a site in G1 referred to as the restriction point 
(R) and enter a state of quiescence known as G0.  Additionally, nutrient availability also regulates 
G1 cell cycle progression.  While there is a vast literature on the regulation of G1 cell cycle 
progression, there remains confusion as to the nature of G1 cell cycle checkpoints – especially 
regarding the temporal location of R and nutritional sensing.  In this report, using sequential 
blocking experiments we show that the GF-mediated R can be distinguished from G1 cell cycle 
checkpoints mediated by essential amino acids, glutamine, and mTOR.  We demonstrate different 
profiles for cell cycle regulators when released from restriction point relative to the metabolic 
checkpoints.  Significantly we also show that in addition to GF autonomy, cancer cells also have 
dysregulated nutritional sensing.  These data are consistent with a mid-G1 R where cells decide 
whether they should divide, followed by late-G1 metabolic checkpoints where cells determine 
whether they have sufficient nutrients to divide.  Since rapamycin and Torin1 arrest cells the latest 




Materials and Methods 
Cells and cell culture conditions.  The BJ hTERT, MCF7, MDA-MB-231, and Panc-1 cells used 
in this study were obtained from the American Tissue Type Culture Collection.  All the cells were 
maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine 
serum (Sigma). 
 
Materials.  Reagents were obtained from the following sources: Antibodies against Akt, phospho-
Akt (T308 and S473), S6K, phospho-S6K (T389), 4EBP1, phospho-4EBP1, LC3-II, Rb, phospho-
Rb (T807/811), cyclin E, and actin were obtained from Cell Signaling; antibodies against p21 and 
p27 were obtained from Santa Cruz Biotechnology; antibody against cyclin D was obtained from 
BD Biosciences; and anti-mouse and anti-rabbit HRP conjugated secondary antibodies were 
obtained from Promega.  DMEM (D6429), DMEM lacking Gln (D5546), DMEM lacking Arg, Leu 
and Lys (D9443), dialyzed fetal bovine serum (F0392), and glutamine (G7513) were obtained from 
Sigma.  Rapamycin was obtained from LC Laboratories, and Torin1 was obtained from Tocris.  
Ultima Gold scintillation fluid (6013681) and [
3
H]-thymidine (NET-027E) were obtained from 
Perkin Elmer.  
 
Western Blot Analysis.  Proteins were extracted from cultured cells in M-PER (Thermo Scientific, 
78501).  Equal amounts of proteins were subjected to SDS-PAGE on poly-acrylamide separating 
gels.  Electrophoresed proteins were then transferred to nitrocellulose membrane.  After transfer, 
membranes were blocked in an isotonic solution containing 5% non-fat dry milk in PBS.  
Membranes were then incubated with primary antibodies as described in the text.  Depending on the 
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origin of the primary antibody, either anti-mouse or anti-rabbit HRP conjugated IgG was used for 
detection using ECL system (Pierce).  
 
Thymidine Incorporation Assay.  To determine the progression from G1 to S-phase, cells were 
labeled with 1µCi/ml [
3
H]-thymidine.  At indicated times, cells were washed twice with 1ml PBS, 
then precipitated twice with 1ml 10% TCA.  The precipitates were solubilized in 0.5 ml of 0.5% 
SDS/0.5M NaOH solution, and the extent of thymidine incorporation was quantified using 75 µl of 
sample and 3 ml of scintillation fluid. 
 
Flow cytometric analysis.  Cultured cells were washed and trypsinized.  Cell suspensions were 
recovered and resuspended in the following fixing solution: 7ml 1X phosphate buffered saline, 2% 
bovine serum albumin, 5mM EDTA, 0.1% NaN3.  3ml of 100% ethanol was added drop wise. Fixed 
cells were centrifuged, washed, and then resuspended in 500µl sorting buffer: 1X phosphate 
buffered saline, 0.1% Triton-X 100, 2% bovine serum albumin, 5mM EDTA, 40µg/ml propidium 
iodide, 100µg/ml RNAse A, and incubated at 37C for 30 min.  The cells were filtered through 70-
µm mesh to remove cell aggregates. The DNA content was analyzed by flow cytometry 
(FACSCalibur; Becton Dickinson), and percentages of cells within each phase of the cell cycle were 




Growth Factor and amino acids deprivation, as well as mTOR inhibition induce G1 cell cycle 
arrest. 
It has been reported that many cancer cell lines do not arrest in G1 upon GF deprivation, and 
indeed autonomy from GF signaling is one of the hallmarks of cancer (41).  We therefore used the 
human foreskin fibroblast BJ hTERT cells, which are immortalized by introduction of telomerase to 
prevent replicative senescence (42), to characterize the G1 arrest upon GF and nutrient deprivation 
or mTOR inhibition.  BJ hTERT cells were shifted to medium lacking GF, EAA, Q, or complete 
medium containing 20 M rapamycin or 250 nM Torin1 for 24 or 48 hr.  High dose (20 M) 
rapamycin is required to get complete G1 arrest by virtue of being able to suppress phosphorylation 
of the mTORC1 substrate eukaryotic initiation factor 4E-binding protein-1 (4E-BP1) (43).  To 
monitor progression into S-phase, the cells were labeled using [
3
H]-thymidine for the final 24 hr of 
treatment.  As shown in Fig. 3A, GF, EAA, or Q deprivation causes 50-70% decrease in [
3
H]-
thymidine incorporation in initial 24 hr.  However, by 48 hr, thymidine incorporation reduced to 
less than 5% of control, indicating complete cell cycle arrest under these conditions.  Rapamycin 
caused complete arrest at both 24 and 48 hr of treatment. 
We next examined cell cycle distribution in BJ cells by measuring DNA content using flow 
cytometry.  The cells were placed in various blocking conditions for 48 hr, fixed and stained using 
propidium iodide and analyzed by FACS.  The cells had a marked increase in G1 cell population at 
the expense of S- and G2/M-phase cells upon serum deprivation and to a lesser extent with 
rapamycin (Fig. 3B).  However upon EAA and Q deprivation, BJ cells maintained their S-phase 
DNA content despite the observation in Fig. 3A that there was no DNA synthesis after 48 hr of 
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deprivation.  This would indicate that for cells in S-phase, the lack of either EAA or Q prevents 
cells from progressing out of S-phase (Fig. 3B).  
To determine whether cells are capable of re-entry into cell cycle, we measured the kinetics 
for progression into S-phase upon release from various arrested states.  In brief, cells were placed in 
various blocking conditions for 48 hr.  Cells were then released from the block by replacing with 
complete medium, and pulsed with [
3
H]-thymidine for 1 hr at indicated time points (0 to 28 hr).  As 
shown in Fig. 3C, cells starting from G0 (GF deprivation) took approximately 16 hr to enter the S-
phase.  Cells starting from rapamycin block also entered the S-phase after 16 hr.  Surprisingly, cells 
starting from EAA or Q block began synthesizing DNA with a longer lag phase of 18 to 20 hr.  
While there are a small fraction of cells in S-phase (5 – 15%) with various blocking conditions as 
seen by flow cytometry (Fig. 3B), the prolonged lag phase along with low baseline and sharp 
transition indicates that thymidine incorporation occurs predominantly from G1-phase cells released 
from blocking conditions into S-phase (Fig. 3C).  Our observation for the time required to traverse 
from G0 to S-phase is similar to what has been described previously (44-46).  Thus, the kinetic 
analysis shows that cells are able re-enter the cell cycle upon release from various blocking 
conditions.  These data also reveal differences in recovery times after being subjected to EAA, Q 
and GF deprivation; however they do not provide insight as to the temporal relationships of the 






GF, EAA, Q, and rapamycin mediated G1 cell cycle arrests are distinct and distinguishable 
In order to distinguish G1 cell cycle arrest caused by different blocking conditions, we 
performed a series of sequential blocking experiments.  In brief, cells were exposed to various 
blocking conditions for 48 hr to cause complete arrest.  At this point, the first block was removed 
and a second block was applied along with [
3
H]-thymidine for 24 hr.  If the second block applied is 
either at the same point or downstream of the first block, then [
3
H]-thymidine incorporation should 
not occur.  However, if the second block site is upstream of the first block, then the cells should 
progress into S-phase and incorporate the label.  The extent of [
3
H]-thymidine incorporated by cells 
released into complete medium after various first blocks was considered to be 100%.  As shown in 
Fig. 4A, when GF deprivation was applied as the first block and when either EAA or Q deprivation, 
or rapamycin treatment were applied as second blocks, there was very little [
3
H]-thymidine 
incorporation – indicating that the GF arrest site is either upstream or at the same site as other 
blocking conditions.  When EAA deprivation was applied as the first block (Fig. 4B), followed by a 
second block of GF deprivation, increased [
3
H]-thymidine incorporation was seen.  However, with 
either Q deprivation or rapamycin treatment as the second block, no significant [
3
H]-thymidine 
incorporation was observed.  When Q deprivation was applied as the first block (Fig. 4C), only 
rapamycin treatment as the second block prevented progression into the S-phase, whereas a second 
block of GF or EAA deprivation failed to arrest the cells.  Lastly, when rapamycin treatment was 
applied as a first block followed by GF, EAA, or Q deprivation as the second block, there was an 
increase in [
3
H]-thymidine incorporation in all the cases, indicating that all the blocks are upstream 
of rapamycin arrest site (Fig. 4D).  Taken together, the data indicates that the arrest sites mediated 
by various blocking conditions are distinguishable, in the order of GF  EAA  Q  mTOR (Fig. 
4E). 
 18 
Temporal mapping of theG1 cell cycle checkpoints 
To better understand the temporal map shown in Fig. 4E, we examined the ability of EAA, 
Q, and rapamycin to block G1 cell cycle progression after release from G0.  Cells were 
synchronized in G0 using serum deprivation for 48 hr.  The cells were reinitiated into cell cycle by 
providing complete medium and [
3
H]-thymidine.  At indicated time points, cells were shifted to 
various blocking conditions to determine the point when blocking no longer prevented entry into S-
phase (schematic shown in Fig. 5A).  As shown in Fig. 5B, starting from G0, EAA or Q withdrawal 
until 12 hr caused the cells to arrest in G1, after which their withdrawal did not arrest the cells as 
evidenced by increased thymidine incorporation.  Addition of rapamycin continued to suppress 
thymidine incorporation until 16 hr after release from G0, as did a catalytic inhibitor of mTOR – 
Torin1.  This suggests that EAA and Q checkpoints are 12 hr from G0 and are upstream from 
rapamycin-mediated arrest, which apparently is very close to the G1/S border since it takes 16 hr 
from the time of restoring GF to increased thymidine incorporation (Fig. 3C). 
 
Restriction point and metabolic checkpoint arrest lead to differential patterns of cell cycle 
regulator expression and phosphorylation 
The data in Figs. 4 and 5 indicate a temporal difference in the ability of GF, EAA, and Q 
deprivation, and rapamycin to arrest cells in G1.  To further establish that the cell cycle checkpoints 
are distinct – especially between the EAA and Q checkpoints, which apparently are temporally very 
close to each other – we examined the impact on cell cycle regulatory signals.  A key cell cycle 
regulatory signaling pathway is mediated by phosphatidylinositol-3-kinase (PI3K) and Akt signals 
that impact on mTOR (47).  Akt is phosphorylated at Thr308 in response to GF stimulation of PI3K 
activation (48).  As expected, GF deprivation led to a decrease in Akt phosphorylation at Thr308 
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(Figs. 6A and 6B).  There was also a decrease in Akt phosphorylation at Ser473 - a downstream 
target of mTORC2 (49).  There was a marked decrease in phosphorylation of p70-S6 kinase 
(p70
S6K
) and a smaller decrease in the phosphorylation of 4EBP1 upon GF deprivation.  In contrast, 
EAA and Q deprivation had no effect on Akt phosphorylation at either Thr308 or Ser473, indicating 
no effect on PI3K or mTORC2 activity (Figs. 6A and 6B).  However, both EAA and Q deprivation 
did suppress p70
S6K
 phosphorylation.  Interestingly, EAA deprivation suppressed 4E-BP1 
phosphorylation, whereas Q deprivation did not – revealing a differential impact on mTORC1 in 
response to EAA and Q deprivation (Figs. 6A and 6B).  Treatment of cells with rapamycin led to no 
noticeable change in Akt phosphorylation at either Thr308 or Ser473.  As expected, rapamycin 
suppressed the phosphorylation of both mTORC1 substrates p70
S6K
 and 4EBP1.  We also examined 
the impact of nutrient and GF deprivation on autophagy by looking at increased levels of the 
autophagy marker LC3-II.  Significantly, EAA, but not Q deprivation increased LC3-II levels.  As 
expected, rapamycin treatment, which is known to induce autophagy (50), also led to increased 
levels of LC3-II (Figs. 6A and 6B).  Thus, although all of the conditions used here cause G1 cell 
cycle arrest, they impact differentially on PI3K and mTOR kinase activity supporting the hypothesis 
that the checkpoints identified represent distinct sites in G1 – especially between the two amino acid 
sites.  
We next examined the impact of different blocking conditions on known G1 cell cycle 
regulators.  For this approach, cells were placed under various blocking conditions for 48 hr and 
subsequently released by restoring complete medium.  Cell lysates were collected at indicated time 
points and analyzed for phosphorylated-Rb (P-Rb), Rb, cyclin D, and p21 using Western blot 
analysis.  For cells arrested by GF deprivation, we see much less Rb protein and P-Rb Ser807/811 at 
time 0, but there was a dramatic increase in both Rb protein and P-Rb Ser807/811 levels from 11 hr 
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onwards (Figs.6C and 6D).  A similar Rb profile was seen with cells starting from a Q deprived 
state.  However, for cells starting from the EAA deprived state, there were high levels of Rb at time 
0 that did not change much after restoring the EAA.  This effect was clearly distinct from that seen 
with Q deprivation, where there were much lower levels of both Rb and P-Rb.  Rapamycin 
treatment did not significantly reduce the levels of Rb protein or P-Rb - indicating that cells had 
arrested in late-G1 where Rb is already hyperphosphorylated.  Passage through R correlates with an 
increase in cyclin D levels (51).  Upon restoration of complete medium to GF-deprived cells, there 
was a significant increase in the level of cyclin D1 between 5 and 14 hr (Fig. 6E).  In contrast, cells 
starting from EAA, Q, or rapamycin blocking conditions showed lesser changes in cyclin D1 levels 
– indicating a clear distinction between the GF-dependent R and the later nutrient-dependent 
metabolic checkpoints.  Cells starting from all blocking conditions showed very similar cyclin E 
profiles, with cyclin E levels increasing from 11 hr onwards (data not shown).  The CDK inhibitor 
p21 plays complex roles in controlling G1 cell cycle progression.  For cells starting from GF-
deprived state, there was very little p21 at time 0 but its level increased significantly by 2 hr and 
then dropped after 7 hr (Fig. 6F).  The drop in p21 levels coincided with the increase in cyclin D 
levels and Rb phosphorylation at S807/811 (Figs. 6C and 6E).  With EAA and Q deprivation, there 
were very low levels of p21 at time 0 for EAA and high levels with Q – again clearly distinguishing 
these two checkpoints.  With rapamycin block there was very little p21 at time 0 that was 
maintained over the 20 hr time course.  Collectively, the data in Fig. 6 reveal differential impact of 
various blocking conditions on the expression and phosphorylation of cell cycle regulatory proteins.  
While the data do not provide mechanistic insight into cell cycle arrests mediated by different 
blocking conditions, they clearly establish that the cell cycle arrest caused by various blocking 
conditions represent unique cell cycle checkpoints. 
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Metabolic checkpoints are dysregulated in cancer cells 
Complementing genetic mutations required for transformation suggest that in addition to GF 
autonomy, cancer cells may also have dysregulated metabolic checkpoints to allow progression 
through both R and the late-G1 metabolic cell growth checkpoints.  To further characterize the 
impact of GF and nutritional inputs in cancer cells, we examined cell cycle distribution in three 
human cancer cell lines.  Cells were placed in various blocking conditions for 48 hr and analyzed by 
flow cytometry.  MCF7 breast cancer cells had a marked increase in G1 cell population at the 
expense of S-phase cells with serum or amino acid deprivation and rapamycin treatment (Figs. 7A 
and 7D top panel).  The G2/M-phase cells remained constant indicating a G2/M-phase arrest of 
cells as was observed for BJ cells deprived of EAAs in Fig. 3B.  The BJ cells deprived of Q 
displayed an S-phase and G1 phase arrest, but not a G2/M arrest (Fig. 3B) indicating a differential 
sensitivity to EAA and Q for the MCF7 breast cancer cells.  In stark contrast to both the BJ cells 
and the MCF7 cells, MDA-MB-231 breast and Panc-1 pancreatic cancer cell lines displayed a 
dramatic loss of any G1-phase arrest in response to both EAA and Q deprivation (Figs. 7B, 7C, and 
7D middle and lower panel).  Both of these cell lines retained a G1 arrest in response to serum 
withdrawal.  This observation supports the hypothesis that the cells have a mechanism for arresting 
in S- and G2/M-phase upon EAA and Q deprivation.  Importantly, it also demonstrates that the 
ability of EAA and Q to arrest in G1 has been lost in the MDA-MB-231 and Panc-1 cells.  
Rapamycin caused an increase in the G1 cell population in all the cell lines tested, indicating that 
inhibition of mTORC1 activity is sufficient to cause G1 cell cycle arrest.  These observations 
indicate that EAA and Q sensing acts through separate mechanism than rapamycin treatment or GF 
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sensing to cause G1 arrest, and that metabolic deregulation in these cancers cause override of G1 
cell cycle arrest upon amino acid deprivation. 
 
Discussion 
In this report, we have provided evidence that the GF-mediated R and nutrient-mediated 
metabolic checkpoints are distinct and distinguishable.  Sequential blocking experiments show that 
R is upstream of two amino acid checkpoints that are upstream from a checkpoint mediated by 
mTOR.  Although the checkpoints mediated by EAA and Q were temporally close, they could be 
distinguished by sequential blocking and by distinct profiles of cell cycle regulatory protein 
expression and phosphorylation.  Suppression of mTOR with rapamycin blocked cell cycle 
progression significantly later in G1 than amino acid deprivation.  Collectively, this study 
distinguishes the GF-dependent R, which assesses whether it is appropriate for the cell to divide, 
from a series of metabolic checkpoints late in G1 that determine whether division is feasible.  In 
addition to mediating unique late-G1 checkpoints, our data also reveals novel sensing requirements 
for EAA and Q in S- and G2/M-phase of the cell cycle (Fig. 8A).  Using Swiss 3T3 cells, Yen and 
Pardee had previously found that GF deprivation led to mid-G1 arrest whereas isoleucine 
deprivation caused late-G1 and S-phase arrests (52).  This result more closely approximates the 
findings reported here with the human BJ fibroblasts. 
It was somewhat surprising that inhibiting mTOR blocked cell cycle progression 
downstream of EAA.  It is well established that mTORC1 is responsive to EAA (53).  Thus, it was 
anticipated that the absence of EAA would block cell cycle progression at the same place as 
rapamycin.  This was clearly not the case – there was a two-hour difference in the time it took for 
EAA deprivation to no longer prevent progression to S-phase relative to rapamycin (Fig. 5B).  
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However, mTORC1 is also responsive to glucose (54), ATP levels (55), and phosphatidic acid (56), 
a critical intermediate in the synthesis of membrane lipids (57).  Thus, mTOR may not be fully 
active until it has sensed sufficient glucose, ATP, lipids, in addition to EAA.  Thus mTOR likely 
serves as a master regulator that senses complete nutritional sufficiency before committing to 
replicating the genome. 
An important conclusion from this study is the distinguishing of R in mid-G1 from the late-
G1 metabolic checkpoints that control entry into S-phase.  The point in G1 where the cells are no 
longer sensitive to the withdrawal of growth factors (R) has been mapped by Zetterburg and 
colleagues to about 3.5 hr in virtually all mammalian cells tested (3).  The metabolic checkpoints 
downstream from R in this report are similar to a series of checkpoints in yeast collectively known 
as START (7, 58), where nutritional sufficiency is evaluated in a TOR-dependent manner in yeast 
(6, 59).  R has commonly been referred to as the mammalian equivalent of START, but as shown 
here, the metabolic checkpoints that correspond with START are clearly distinguishable from R.  It 
is likely that R evolved much later than START as a means for multicellular organisms to regulate 
proliferation through intercellular communication.  
Part of the controversy over the location of a growth factor-dependent R is that different 
groups have reported responsiveness to growth factors later in G1 than described by Zetterberg (3). 
Notably Pledger and Stiles reported that PDGF could stimulate quiescent cells to “competence” 
with a short duration of treatment (60). These competent cells could then be induced to progress 
through the remainder of G1 by “progression” factors like insulin-like growth factor-1 (IGF1) (60). 
Similar studies with hepatocytes induced from quiescence showed a growth factor dependence that 
likely was extended into later stages of G1 (61, 62). The major distinction between these studies and 
Zetterberg’s work was that the Zetterberg study followed cells from mitosis, whereas the other 
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studies looked at cells leaving quiescence. Thus, cells starting from quiescence or G0 and cells 
starting from mitosis apparently have different needs for progression to S-phase. What was clear 
from the Zetterberg study was that after approximately 3.5 hr post mitosis, if serum growth factors 
were removed, cells did not enter quiescence and proceeded through S-phase to mitosis without any 
additional growth factor stimulation. In our double block experiments, the cells arrested by amino 
acid depletion or rapamycin could proceed to S-phase in the absence of growth factors upon 
restoration of amino acids or removal rapamycin. This is especially relevant for the mTOR 
checkpoint, since mTOR is activated in response to IGF1 and other growth factors. Importantly, the 
cells that arrested in G1 in response to amino acid deprivation and rapamycin, like in the Zetterberg 
study, were coming from mitosis, not quiescence, and therefore did not need growth factors to 
proceed to S-phase. This would indicate that under conditions where cells have passed through 
mitosis and avoided quiescence, mTOR does not need additional growth factor stimulation. 
However, this is apparently not the case when cells are coming out of quiescence where further 
stimulation of mTOR by IGF1 may be required. 
GF autonomy is one of the more significant hallmarks in cancer (41).  However, it has been 
suggested that mutations leading to elevated mTOR kinase activity are the most common mutations 
in observed human cancer (63, 64).  Moreover, dysregulation of cellular metabolism is considered 
as an emerging hallmark of cancer (12).  Several oncogenes and survival signals have been shown 
to directly upregulate glycolytic enzymes and induce metabolic reprogramming (15-17).  Consistent 
with this emerging role for metabolism in cancer cells, we have demonstrated here that nutrient 
sensing metabolic checkpoints are dysregulated in cancer cells.  Surprisingly, MDA-MB-231 breast 
cancer cells and Panc-1 pancreatic cancer cells deprived of EAA and Q arrested in S and/or G2/M-
phase – indicating an override of the G1 arrest observed in normal BJ fibroblasts and MCF7 breast 
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cancer cells.  Thus, the late-G1 metabolic checkpoints, like R, are apparently dysregulated as well.  
Of interest was the apparent “freeze” in cell cycle progression in the BJ cells in response to amino 
acid deprivation – indicating that collection of cells in S- and G2/M-phase in cancer cells is a 
property of the normal cells.  It is also possible that cells could synthesize glutamine and also obtain 
other essential amino acids through autophagy causing reversibility of the checkpoints, enabling 
them to tide over the late-G1 metabolic checkpoints and thereby collect in other phases of cell 
cycle.  As shown in our model (Fig. 8B), in addition to genetic defects that confer autonomy to GF 
signaling, we hypothesize that specific genetic mutations override the late-G1 nutritional 
checkpoints causing them to arrest in S- and G2/M-phase of the cell cycle, where we have shown 
that additional amino acid sensing occurs through as yet unknown mechanisms.  Cancer cells 
arrested in S- and G2/M-phase are uniquely sensitive to the apoptotic insult of DNA damaging 
agents.  Thus, synthetic lethality created by interfering with Q utilization and phase-specific 





Figure 3.  Growth factor and amino acid deprivation, as well as mTOR inhibition induce G1 
cell cycle arrest. 
(A) BJ hTERT cells were plated at 20% confluence in DMEM containing 10% FBS for 24 hr at 
which time they were shifted to complete medium (CM) or various blocking conditions [-GF,-EAA, 
-Q, +Rapamycin (20 M)] for 24 or 48 hr.  The blocking conditions for Q used DMEM lacking Q; 
and for EAA, DMEM lacking Leu, Lys, and Arg as described in Material and Methods.  The CM 
contained 10% DFBS (dialyzed FBS) instead of 10% FBS.  Cells were labeled with [
3
H]-thymidine 
(TdR) for the initial or final 24 hr of treatment, after which the cells were collected and the 
incorporated label was determined by scintillation counting as described in Materials and Methods.  
Error bars represent the standard error for the experiment repeated at least four times. (B) BJ cells 
were plated and shifted to CM or various blocking conditions for 48 hr as in (A), after which the 
cells were harvested and analyzed for cell cycle distribution by measuring DNA content/cell as 
described in Materials and Methods.  Error bars represent the standard error from independent 
experiments repeated four times.  (C)To investigate the kinetics for progression into S-phase, BJ 
cells were plated and shifted to blocking conditions for 48 hr as in (A).  Cells were subsequently 
released by shifting to complete medium, and pulsed with [
3
H]-thymidine (TdR) at indicated time 
points for 1 hr after which the cells were collected and the incorporated label was determined.  Error 











Figure 4.  GF, EAA, Q, and rapamycin mediated G1 cell cycle arrests are distinct and 
distinguishable. 
(A-D)  BJ hTERT cells were plated and shifted to various first blocking conditions for 48 hr as in 
Fig. 3A.  The cells were subsequently shifted to CM or different second block conditions containing 
[
3
H]-thymidine (TdR) for 24 hr, after which the cells were collected and the incorporated label was 
determined.  Error bars represent the standard error for the experiment repeated at least four times.  
(E) Schematic model showing relative positions of different metabolic checkpoints relative to R 
(not drawn to represent precise time scales).  G1-pm is post-mitotic phase in G1, G1-ps is pre-S 









Figure 5.  Temporal mapping of the metabolic checkpoints from G0. 
(A) Schematic representation of the experiment shown in (B).  (B) BJ cells were plated as in Fig. 
3A for 24 hr.  Cells were synchronized in G0 by shifting to DMEM+1mM Q lacking GF for 48 hr.  
The cells were released from G0 by shifting to CM containing DMEM (1mM Q) and 1 µCi/ml [
3
H]-
thymidine.  Various blocking conditions along with [
3
H]-thymidine were applied at indicated time 
points.  After 36 hr from the release from G0, cells were collected and the incorporated label was 
determined.  This experiment utilized DMEM with reduced Q (1 mM vs. 4 mM) because Q 
withdrawal following DMEM with high Q did not give strong G1 arrest.  Error bars represent the 











Figure 6.  Restriction point and metabolic checkpoint arrest lead to differential patterns of 
cell cycle regulator expression and phosphorylation. 
(A) Cells were plated at 30% confluence in 10-cm plates in DMEM containing 10% FBS.  After 24 
hr, the cells were shifted to CM or blocking conditions for 4 hr, at which time the cells were 
harvested and the levels of the indicated protein or phosphoprotein was determined by Western blot 
analysis.  The data shown are representative of experiments repeated at least two times.  (B)  
Quantitative analysis of relative protein levels for Western blots shown in (A) using ImageJ 
software.  (C-F) BJ cells were plated and shifted to various blocking conditions for 48 hr as in Fig. 
3A.  The cells were subsequently released by shifting to CM, and the cells were harvested and 
lysates collected at indicated time points.  The levels of the indicated protein or phosphoprotein 
were determined by Western blot analysis.  The data shown are representative of experiments 
repeated at least two times.  Also shown in the line graphs are the kinetic analyses of relative 










Figure 7.  Metabolic checkpoints are dysregulated in cancer cells. 
MCF7(A), MDA-MB-231 (B), and Panc-1 (C) cells were plated at 20% confluence in 10-cm plates 
in DMEM containing 10% FBS.  After 24 hr, the cells were shifted to CM or various blocking 
conditions for 48 hr, at which time the cells were harvested, fixed, stained with propidium iodide, 
and analyzed for distribution in different phases of cell cycle by measuring DNA content/cell as 
described in Materials and Methods.  Error bars represent the standard error from independent 
experiments repeated four times.  Table with the mean and standard error for the graphs is also 
shown.  (D) Representative flow histograms showing increases in S- and G2/M-phase cell 









Figure 8.  Restriction point and metabolic checkpoints are distinct, and dysregulated in cancer 
cells. 
(A)  In non-transformed primary cell, intact GF-mediated mid-G1 R and amino acid and mTOR 
mediated late-G1 “Cell Growth Checkpoint” is shown.  The proposed cell growth checkpoint, but 
not R, is likely evolutionally related to START in yeast.  We present evidence here suggesting that 
G1 checkpoints are ordered as GF  EAA  Q  mTOR, such that mTOR acts as a final arbiter 
before committing to DNA replication.  Besides mediating unique late-G1 checkpoints, novel 
sensing requirements for EAA and Q in S- and G2/M-phase of the cell cycle is also shown.  (B)  In 
cancer cell, autonomy from GF signaling and deregulation of metabolic checkpoint is modeled.  
mTOR serves as a master regulator coupling cell growth to nutritional sufficiency, and its sole 
inhibition was found to be sufficient to cause G1 arrest in all the cell lines used in this study.  
Additional EAA and Q sensing is also shown in S- and G2/M-phase of the cancer cell cycle, such 
that in the event of late-G1 metabolic checkpoint override, cancer cells arrest in S- and G2/M-phase 











Chapter 3:  Blocking anaplerotic entry of glutamine to TCA cycle sensitizes K-Ras mutant 
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Cancer cells engage in aerobic glycolysis to meet their increased anabolic demands.  In the absence 
of glucose-generated acetyl CoA, cancer cells rely on glutamine to support the anaplerotic citric 
acid cycle.  We report here that glutamine depletion causes K-Ras mutant cancer cells to arrest in S- 
and G2/M-phase of the cell cycle, whereas cancer cells with WT K-Ras arrest in G1 phase.  
Inhibition of K-Ras pathway using MEK inhibitor U0126 or mTOR pathway using catalytic 
inhibitor Torin1 does not cause reversal to G1 arrest upon glutamine starvation.  However, dual 
inhibition of MEK and mTOR pathway restores G1 cell cycle arrest in K-Ras mutant cancer cells 
indicating that cross-talk between K-Ras and PI3K/mTOR pathway is required to override the 
glutamine mediated G1 arrest.  Treatment with aminooxyacetate (AOA), a glutamate oxaloacetate 
transaminase (GOT) inhibitor, mimics glutamine deprivation, causing S- and G2/M-phase arrest in 
K-Ras mutant cancer cells.  Significantly, glutamine deprivation or AOA treatment causes enhanced 
sensitivity to phase-specific cytotoxic drugs, Capecitabine and Paclitaxel.  Besides providing novel 
strategies for therapeutic intervention, our data suggest that cancers with specific oncogenic drivers 
and atypical metabolic addictions could offer an increased therapeutic index to currently existing 
chemotherapeutic regimens. 
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Materials and Methods 
Cells and cell culture conditions.  The Calu-1, DU-145, LNCaP, MCF7, MDA-MB-231, and 
Panc-1 cells used in this study were obtained from the American Tissue Type Culture Collection.  
LNCaP cells were maintained in RPMI-1640, and all the other cells were maintained in DMEM 
supplemented with 10% fetal bovine serum (Sigma) and penicillin/streptomycin (Sigma). 
 
Materials.  Reagents were obtained from the following sources: Antibodies against phospho-Akt 
(T308 and S473), phospho-S6K (T389), phospho-4EBP1 (T37/46), phospho-ERK1/2 (T202/Y204), 
phospho-Rb (S807/811), cyclin E, cleaved PARP, and actin were obtained from Cell Signaling; 
antibody against p27 was obtained from Santa Cruz Biotechnology; antibodies against cyclin A, 
cyclin B, and cyclin D were obtained from BD Biosciences; and anti-mouse and anti-rabbit HRP 
conjugated secondary antibodies were obtained from Promega.  DMEM (D6429), DMEM lacking 
Gln (D5546), RPMI-1640 (R8758), RPMI-1640 lacking Gln (R0883), dialyzed fetal bovine serum 
(F0392), and glutamine (G7513), and aminooxyacetic acid hemihydrochloride (AOA) (C13408), 
were obtained from Sigma.  U0126 (9903) was obtained from Cell Signaling, Torin1 (4247) was 
obtained from Tocris.  Paclitaxel (P-9600) and Capecitabine (C-2799) were obtained from LC 
Laboratories. 
 
Flow cytometric analysis.  Cells were washed twice in phosphate buffered saline (PBS) and 
harvested.  Cell suspensions were resuspended in the following fixing solution: 7ml PBS, 2% 
bovine serum albumin (BSA), 5mM EDTA, 0.1% NaN3; and 3ml of 100% ethanol was added 
dropwise.  Fixed cells were centrifuged, washed using PBS, and then resuspended in 500µl sorting 
buffer: PBS, 0.1% Triton-X 100, 2% BSA, 5mM EDTA, 40µg/ml propidium iodide, 100µg/ml 
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RNAse A, and incubated at 37C for 30 min.  The cells were filtered through 70-µm mesh to remove 
cell aggregates. The DNA content was analyzed by flow cytometry (FACSCalibur; Becton 
Dickinson), and percentages of cells within each phase of the cell cycle were determined using 
WinCycle software (Phoenix Flow Systems). 
 
Cell proliferation assay.  At indicated times, cells in six-well plates were washed once with PBS, 
trypsinized with 500 µl trypsin, resuspended in 500 µl complete medium.  The cells were stained 
using 0.35% crystal violet solution (Millipore), and then counted twice using hemocytometer. 
 
Western Blot Analysis.  Cell lysates were collected using M-PER (Thermo Scientific, 78501), and 
proteins were separated on denaturing SDS-PAGE gels.  Electrophoresed proteins were transferred 
to nitrocellulose membrane.  After transfer, membranes were blocked in an isotonic solution 
containing 5% non-fat dry milk in PBS.  Membranes were incubated with primary antibodies as 
described in the text, and depending on the origin of the primary antibody, either anti-mouse or anti-
rabbit HRP conjugated IgG was used for detection using ECL system (Pierce).  
 
Trypan blue exclusion cell viability assay.  At indicated time points post-treatment, floating and 
adherent cells were collected and pelleted by centrifugation.  The cell pellet was resuspended in 500 
µl PBS, stained using 500 µl 0.4% trypan blue dye (Sigma), and incubated at room temperature for 
10 min.  Both dead (stained) and live (unstained) cells were counted twice using hemocytometer, 




Glutamine deprivation causes S- and G2/M-phase arrest in K-Ras mutant cancer cells. 
Glutamine deprivation is known to cause G1 cell cycle arrest in nontransformed primary 
cells (2, 65).  We have previously shown that MDA-MB-231 breast and Panc-1 pancreatic cancer 
cell lines fail to arrest in G1 upon glutamine or essential amino acid deprivation (Fig. 7).  We 
therefore screened several cancer cell lines to identify the underlying genetic mutations that 
override the amino acid mediated G1 checkpoint.  As seen in figure 9A, glutamine deprivation for 
48 hr caused significant accumulation of cells in G1 phase at the expense of S- and G2/M-phase 
cells in MCF7 breast, and DU-145 and LNCaP prostate cancer cell lines.  On the other hand, 
glutamine deprivation caused accumulation of S- and G2/M-phase cells along with a reduction in 
G1 cell population in MDA-MB-231 breast, PANC-1 pancreatic, and Calu-1 lung cancer cells.  The 
cell lines that failed to arrest in G1 upon glutamine deprivation were found to have oncogenic K-
Ras mutation (Fig. 9B).  However, failure to arrest in G1 upon glutamine deprivation in these K-Ras 
mutant cancer cell lines was neither tissue specific nor K-Ras mutation site specific.  In all the cell 
lines, irrespective of cell type and K-Ras status, cells appeared significantly smaller in size and 
rounded upon glutamine deprivation (Fig. 9C) suggesting that glutamine deprivation causes 
alterations in actin cytoskeleton.  There were also fewer cells in glutamine deprived condition.  To 
further establish that glutamine deprivation was not merely prolonging S phase and thereby causing 
increased accumulation in S-phase, we performed cell proliferation assay.  In all the cell lines 
tested, there was a significant loss of cell proliferation upon glutamine deprivation (Fig. 9D).  Taken 
together, the data shows that glutamine deprivation causes G1 cell cycle arrest in K-Ras WT cells, 
and S- and G2/M-phase arrest in K-Ras mutant cancer cells. 
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Glutamine deprivation induces loss of cyclin D/cyclin E and p27 protein expression in K-Ras 
mutant cancer cells. 
To further elucidate the differences between K-Ras mutant and WT cells, we next compared 
the effects of glutamine deprivation on PI3K/mTOR kinase activity.  Glutamine deprivation caused 
decrease in S6K phosphorylation but not 4EBP1 phosphorylation in both K-Ras WT and mutant 
cancer cells (Fig. 10A).  This was similar to the response seen in non-transformed BJ fibroblasts 
(Fig. 6A and 6B).  Release of feedback inhibition upon suppression of S6K phosphorylation led to 
increase in Akt-S473 phosphorylation in K-Ras mutant cells, but not in K-Ras WT cells.  There was 
also an increase in Akt-T308 phosphorylation upon glutamine deprivation. 
We next analyzed cell cycle regulator expression and phosphorylation profile to further 
assess the impact of glutamine deprivation on K-Ras WT and K-Ras mutant cancer cells.  K-Ras 
WT cells showed a decreased in cyclin B protein levels, indicating that there were fewer cells in the 
G2/M-phase upon glutamine deprivation (Fig. 10B).  This is consistent with the flow cytometry 
data showing an increase in G1 cell population (Fig. 9A).  However, cyclin D, cyclin E, and cyclin 
A levels were unchanged upon glutamine deprivation in K-Ras WT cells.  It is possible that 
glutamine deprivation causes G1 arrest in these cells by influencing the association of these cyclins 
with the CDKs and not on the protein levels itself.  However, in the case of K-Ras mutant cancer 
cell lines, glutamine deprivation caused loss of cyclin D, cyclin E, and p27 protein levels and an 
increase in cyclin A protein expression (Fig. 10B), which is also consistent with the flow cytometric 




Inhibition of K-Ras effector pathways restores G1 arrest upon Q deprivation. 
The data in Figure 9 reveal a correlation between K-Ras mutation and dysregulated G1 cell cycle 
progression through a Q-dependent checkpoint.  To investigate whether mutant K-Ras is sufficient 
to override the Q-dependent G1 checkpoint, we introduced a vector that expresses mutant K-Ras 
into the immortalized human diploid fibroblast cell line BJ-hTERT (42) and evaluated the impact of 
Q deprivation on cell cycle progression.  As shown in Figure 11A, mutant K-Ras, by itself, failed to 
override G1 cell cycle arrest – indicating that additional genetic alterations in the cancer cells are 
required for dysregulating the Q-dependent G1 checkpoint. 
Based on elegant studies by Weinberg and colleagues on the minimal genetic requirements 
for the transformation of human cells (9, 10), we have proposed that the cooperating genetic 
mutations in human cancer cells impact on signaling pathways that lead to passage through two 
major G1 cell cycle checkpoints (8) that have both been referred to as the restriction point (2).  The 
first checkpoint is in mid-G1 and is dependent on growth factors and facilitates passage through a 
checkpoint regulated by cyclin D and ERK; the second checkpoint is dependent on nutrients 
(including Q) and is regulated by cyclin E and mTOR (66).  Interestingly, both of these pathways 
can be activated by mutant K-Ras (67, 68).  To investigate if either or both of these key regulatory 
pathways are critical for overriding the Q-dependent G1 checkpoint, we investigated whether we 
could restore G1 arrest in response to Q deprivation by pharmacological suppression of the 
Raf/Mek/ERK and the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR (mammalian target of 
rapamycin) pathways (Figure 11B).  We first evaluated the effect of U0126 (Mek inhibitor) and 
Torin1 (mTOR inhibitor) on Q-induced cell cycle arrest in MDA-MB-231 cells.  As shown in 
Figure 11C, in the absence of Q there was the S-phase arrest seen in Figure 9.  By themself, neither 
U0126 nor Torin1 reverted the cells to G1 arrest upon Q deprivation.  However, treatment with 
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U0126 and Torin1 together did revert the cells to G1 arrest in the absence of glutamine (Figure 
11C).  As shown in Figure 11D, U0126 and Torin1 suppressed the phosphorylation of the Mek and 
mTOR substrates ERK and S6 kinase respectively.   We also evaluated the impact of U0126 and 
Torin1 on Q-induced cell cycle arrest in the Panc-1 cells.  Unlike the MDA-MB-231 cells, the 
Panc-1 cells were largely reverted to G1 arrest with only Torin1 – U0126 did not do much by itself 
and marginally improved G1 arrest when combined with Torin1 (Figure 11E).  Neither drug alone 
nor a combination of both, revert the G2/M arrest observed in the Panc-1 cells (Figure 11E).  
Lastly, we examined the MCF7 cells, which do not have a K-Ras mutation and arrest in G1 
in response to glutamine deprivation.  These cells were treated with the tumor-promoting phorbol 
ester12-O-tetradecanoylphorbol-13-acetate (TPA) to stimulate the Raf/Mek/ERK pathway, which is 
commonly activated by mutant K-Ras.  As shown in Figure 11F, TPA treatment caused a shift from 
G1 to S-phase arrest in response to Q deprivation.  This change in arrest pattern could be reverted to 
G1 arrest with U0126, but not with Torin1. Collectively, the data in Figure 11 reveal that multiple 
genetic alterations contribute to override of the Q-dependent G1 cell cycle checkpoint and that 
while K-Ras mutations in human cancer cell lines correlate with override of the Q-mediated G1 
checkpoint, mutant K-Ras by itself is not sufficient to promote passage in the absence of Q.  These 
data also reveal that K-Ras is not required for override of the Q-dependent G1 as revealed by TPA 





Glutamine deprivation sensitizes K-Ras mutated cancer cells to phase-specific cytotoxic drugs. 
We next examined whether differential cell cycle arrest upon glutamine deprivation could 
create synthetic lethality to phase specific cytotoxic drugs in K-Ras mutant cancer cells.  To 
specifically target the S-phase arrested cells, we used capecitabine, a prodrug that is converted 
enzymatically to 5-fluorouracil (5-FU) and elicits DNA damage response leading to apoptosis.  In 
order to target the G2/M-phase arrested cells upon glutamine deprivation, we used paclitaxel which 
stabilizes microtubules and induces apoptotic cell death in the mitotic phase.  As seen in figure 12A 
and B, glutamine deprivation alone led to a modest increase in nonviable cells in both K-Ras WT 
and K-Ras mutant cancer cell lines.  In K-Ras WT cell lines, addition of capecitabine or paclitaxel 
to glutamine deprived cells did not cause significant increases in dead cells compared to the drugs 
added to CM control cells.  However, in MDA-MB-231 and PANC-1 K-Ras mutant cells, 
glutamine deprivation created synthetic lethality to the cytotoxic drugs, and there was a four-fold 
increase in the number of nonviable cells. 
 
Pharmacological inhibition of Q anaplerosis sensitizes K-Ras mutant cancer cells to cytotoxic 
drugs. 
Glutamine, via anaplerotic entry to the TCA cycle, replenishes the intermediates lost by the 
exit of citrate from the mitochondria for fatty acid and cholesterol biosynthesis (69).  Glutaminase 
catalyzes the deamination of Q to generate glutamate.  Glutamate then acts as an amide donor to 
oxaloacetate in the transamination reaction catalyzed by glutamate oxaloacetate transaminase 
(GOT) to generate aspartate and α-ketoglutarate – a key TCA cycle intermediate (schematic shown 
in Figure 13A).  Anaplerotic entry of Q into the TCA cycle can be inhibited by aminoxyacetate 
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(AOA), which inhibits GOT and consequently the entry of glutamine into the TCA cycle (70, 71).  
Treatment of both MCF-7 and MDA-MB-231 cells with AOA for 48 hr led to morphological 
changes similar to that observed with Q deprivation (Figure 13B) – indicating that AOA mimics Q 
deprivation in both cell types.  As seen in Figure 13C, AOA treatment caused G1 arrest in the 
MCF-7 cells and S- and G2/M-phase arrest in the MDA-MB-231 cells – as was observed with Q 
deprivation in Figure 9.  We therefore investigated whether AOA treatment would mimic Q 
deprivation to create the synthetic lethality observed with cell cycle phase-specific cytotoxic drugs 
in K-Ras mutant cancer cells.  AOA treatment by itself led to minimal increase in nonviable cells in 
both MCF-7 and MDA-MB-231 cells (Figure 13D).  AOA treatment alone also did not induce 
significant increases in cleaved PARP (Figure 13D), an indicator of apoptosis – suggesting that 
AOA has low cytotoxicity.  Similar to what was observed with Q deprivation, the combination of 
AOA and the cytotoxic drugs did not increase the percentage of nonviable cells and cleaved PARP 
levels in MCF-7 cells (Figure 13D).  However, the combination of AOA and the cytotoxic drugs 
caused a significant increase in nonviable cells and cleaved PARP levels in MDA-MB-231 cells 
(Figure 13D).  These data indicate that in K-Ras mutant cancer cells, pharmacological inhibition of 
anaplerotic entry of Q into the TCA cycle mimics Q deprivation to produce aberrant cell cycle 






Metabolic transformation is an emerging hallmark in cancer biology.  We have previously 
shown that some cancer cells arrest in S- and G2/M-phase of the cell cycle upon glutamine and 
essential amino acid deprivation.  In this report, we provide evidence showing that cancer cell lines 
harboring K-Ras mutation override the glutamine-mediated G1 cell cycle arrest, and instead cause 
S- and G2/M-phase arrest (Fig. 9A).  Our findings suggest that there are additional amino acid 
sensing mechanisms in S- and G2/M-phase of the cell cycle.  It is possible that glutamine plays 
different roles in different phases of the cell cycle.  There was a profound proliferative defect upon 
glutamine deprivation in all of the cell lines irrespective of the cell type or K-Ras status, and the 
cells also appeared smaller and rounded in morphology.  Consistent with a non-G1 arrest in K-Ras 
mutant cancer cells, glutamine deprivation caused loss of cyclin D/E and p27 protein levels which 
are markers of G1 phase cells (Fig. 10B). 
While there was a correlation between cancer cells harboring K-Ras mutations and override 
of the Q-dependent G1 cell cycle checkpoint, K-Ras, by itself, was not sufficient to induce override 
of the Q-dependent G1 checkpoint.  In addition, we could also induce override of the Q-dependent 
G1 cell cycle checkpoint by treating MCF-7 cells with TPA – indicating it is not strictly a K-Ras-
dependent phenomenon.  However, we have found that other human cancer cell lines harboring K-
Ras mutants display the override of G1 cell cycle arrest caused by Q depletion. 
We found that combining inhibition of both ERK and mTOR could revert the dysregulated 
Q-dependent G1 cell cycle checkpoint in MDA-MB-231 cells.  Panc-1 cells – a human pancreatic 
cancer cell line harboring a K-Ras mutation – that arrested in S and G2/M phase with Q deprivation 
could be largely reverted to G1 arrest with only mTOR suppression.  Thus, it is clear that the 
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override of the Q-mediated G1 checkpoint is complex involving more than one signaling pathway.  
Combined inhibition of two key regulators of G1 cell cycle progression – ERK and mTOR – are 
able to revert the override of the Q-mediated G1 checkpoint, indicating that override is dependent 
on two key signaling nodes implicated at two distinct regulatory G1 checkpoints that have both 
been referred to as the restriction point (66).  There may be other means to accomplish this without 
K-Ras, as observed with TPA-treated MCF-7 cells, but there is a strong correlation with cancer cells 
harboring K-Ras mutations. 
Glutamine deprivation has been shown to be sufficient to cause apoptotic cell death in 
cancer cells with Myc mutation (37).  It has also been reported that glutamine deprivation sensitizes 
cancer cells to redox stress, and drugs such as fenretinide and hydrogen peroxide cause cell death 
upon glutamine deprivation (72, 73).  Based on our finding that glutamine deprivation caused S- 
and G2/M-phase arrest in K-Ras mutant cancer cells and because many cytotoxic drugs used in 
chemotherapy are cell cycle phase-specific, we investigated whether glutamine deprivation could 
create a synthetic lethality to the phase-specific cytotoxic drugs.  Indeed glutamine deprivation 
caused increased sensitivity to both capecitabine and paclitaxel in K-Ras mutant cancer cells, but 
not in K-Ras WT cells (Fig. 12).  To mimic glutamine deprivation, we used AOA which prevents 
anaplerotic glutamine utilization by inhibiting GOT activity.  Flow cytometric analyses showed that 
AOA treatment caused S- and G2/M-phase arrest in MDA-MB-231 K-Ras mutant cancer cells (Fig. 
13).  We also found that similar to glutamine deprivation, AOA treatment also sensitized MDA-
MB-231 cells to phase-specific cytotoxic drugs. 
Glutamine is a conditionally essential amino acid and has been shown to be required for cell 
proliferation and survival.  Consistent with several reports underscoring the importance of 
glutamine in vitro, it has been reported that tumors in vivo also have increased glutamine uptake 
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(74).  To mimic glutamine deprivation in vivo, glutamine analogs DON (6-diazo-5-oxo-L-
norleucine) and acivicin have been used successfully in animal models of cancer.  However, they 
were proven to be unacceptably toxic to humans in clinical trials (37, 75).  The difference could be 
due to cells from different organisms respond differently to amino acid deprivation.  Consistent with 
our findings reported here with human cancer cell lines, K-Ras overexpression has been shown to 
cause abortive S-phase in mouse embryonic fibroblasts (38). 
Ras is mutated in approximately 30% of all cancers and occurs in over 90% of the 
pancreatic cancers (76), which has a 5-year survival rate of less than 5% (77).  However, it is 
considered “therapeutically undruggable” owing in part to its extremely high affinity with GTP (in 
the picomolar range) (78).  We have previously shown that some cancer cell lines arrest outside of 
G1 upon glutamine or EAA deprivation and in this report we show that K-Ras mutation causes G1 
override upon glutamine deprivation.  This aberrant response to amino acid deprivation in general 





Figure 9.  Glutamine deprivation causes S- and G2/M-phase arrest in K-Ras mutant cancer 
cells. 
(A-B) Cells were plated at 30% confluence in 10-cm plates in complete media containing 10% 
serum.  After 24 hr, the cells were shifted to complete medium (CM) or medium lacking Q for 48 
hr.  Both CM and –Q medium contained 10% dialyzed FBS (DFBS).  After 48 hr, the cells were 
harvested, fixed, stained with propidium iodide, and analyzed for cell cycle distribution by 
measuring DNA content/cell as described in Experimental Procedures.  The error bars represent 
standard error of mean for experiments repeated four times.  The mutations present in the cancer 
cell lines were obtained from the Sanger Institute COSMIC database.  (C) Cells were plated and 
treated as described above and after 48 hr cell morphology was examined using phase-contrast 
microscopy.  (D) Cells were plated at 20% confluence in six-well plates in complete media 
containing 10% serum.  After 24 hr (day 1), cells were shifted to CM or medium lacking Q.  Cells 
were harvested at indicated time points, stained using crystal violet, and quantified by light 
microscopy as described in Experimental Procedures.  Error bars represent the standard error for the 












Figure 10.  Cyclin profile correlates with differential cell cycle arrest pattern upon glutamine 
starvation. 
(A)  Cells were plated at 30% confluence in 10-cm plates in complete media containing 10% serum 
for 24 hr, at which time they were shifted to CM or medium lacking Q for 4 hr.  The cells were 
subsequently harvested and cell lysates were collected.  The indicated protein or phosphoprotein 
levels were determined by Western blot analysis.  (B)  The cells were plated and treated as in (A) 
for 48 hr, at which time cells were harvested, lysed, and analyzed for protein levels using Western 









Figure 11.  Dual inhibition of K-Ras and PI3K/mTOR pathway restores G1 arrest in K-Ras 
mutant cancer cells. 
(A) BJ-hTERT human diploid fibroblasts were transfected with either mock control or a vector 
expressing mutant K-Ras (G12V; obtained from Missouri S&T cDNA Resource Center, Rolla, MO, 
USA) using PolyFect transfection reagent (Qiagen, Germantown, MD, USA) per manufacturer’s 
recommendations.  The cells were then put in either complete medium (CM) or in medium lacking 
Q for 48 hr, at which time cell cycle status was determined as in Figure 9A.  (B) Schematic diagram 
of the Raf/Mek/ERK and PI3K/Akt/mTOR signaling pathways that regulate distinct G1 cell cycle 
checkpoints (66).  (C) MDA-MB-231 cells were plated at 30% confluence in 10-cm plates in CM 
containing 10% serum.  After 24 hr, the cells were shifted to CM or medium lacking Q and treated 
with 10 µM U0126 and/or 250 nM Torin1 for 48 hr.  The cells were analyzed by flow cytometry as 
in Figure 9A.  Error bars represent standard error of mean for the experiment repeated four times.  
(D) The MDA-MB-231 cells were similarly treated as in (C) for 4 hr at which time cell lysates were 
prepared and used for Western blot analysis of the levels of phospho-Akt (S473), phospho-S6 
kinase (S6K) (T389), phospho-ERK1/2 (T202/Y204), Akt, S6K, ERK1/2, and actin. The data 
shown is representative of experiments repeated at least two times.  (E) Panc-1 cells were prepared 
and subjected to the same analysis used in (D) for the MDA-MB-231 cells.  (F) MCF7 cells were 
prepared as in (D) and (E) and evaluated similarly as for the MDA-MB-231 and Panc-1 cells except 














Figure 12.  Glutamine deprivation sensitizes K-Ras mutated cancer cells to phase-specific 
cytotoxic drugs. 
(A-D) Cells were plated at 20% confluence in six-well plates in complete media containing 10% 
serum for 24 hr, after which the cells were shifted to CM or medium lacking Q for 48 hr.  After 48 
hr, the cells were additionally treated with 50 nM Paclitaxel or 1 µg/ml Capecitabine for 24 hr.  
Percent cell viability was determined using trypan blue dye exclusion assay as described in 
Experimental Procedures.  The error bars represent the standard error of mean for experiments 









Figure 13.  Pharmacological inhibition of Q anaplerosis sensitizes K-Ras mutant cancer cells 
to cytotoxic drugs. 
(A) Schematic overview of anaplerotic Q utilization.  Q is deaminated to glutamate by glutaminase 
(GLS).  Glutamate is then converted to -ketoglutarateby transamination catalyzed by GOT, which 
uses oxaloacetate as the amino group acceptor to generate aspartate, which can renter the TCA 
cycle via conversion to fumarate in the urea cycle.  AOA blocks the GOT and thusly, the generation 
of -ketoglutarate from Q-derived glutamate.  (B) Cells were plated at 20% confluence in 10-cm 
plates in complete medium (CM) containing 10% serum.  After 24 hr, cells were shifted to CM, or 
medium lacking Q, or CM containing 0.5 mM AOA for 48 hr – at which time the cells were 
observed using phase-contrast microscopy.  (C) MCF7 and MDA-MB-231 cells were plated and 
treated as in (B) for 48 hr, at which time cells were analyzed for cell cycle distribution as in Figure 
9.  Error bars represent standard error of mean for experiments repeated three times.  (D) MCF7 and 
MDA-MB-231 cells were plated as in (A) and shifted to CM and treated with 0.5 mM AOA for 
48 hr.  The cells were additionally treated with 50 nM Paclitaxel or 1 µg/ml Capecitabine for 24 hr, 
at which time the percentage non-viable cells were determined using trypan blue exclusion assay.  
Error bars represent the standard error of mean for experiments repeated three times.  Cell lysates 
were also collected, and the levels of cleaved PARP (antibody from Cell Signaling) were 
determined by Western blot analysis.  Data shown are representative of experiments repeated two 
times.  (E) Model depicting that AOA treatment mimics Q deprivation causing G1 cell cycle arrest 
in K-Ras wild type cells and S- and G2/M-phase arrest in K-Ras mutant human cancer cell lines, 













Chapter 4:  Concluding Remarks and Future Directions 
Based on the rationale presented in chapter 1 regarding the genetic and temporal distinctions 
between GF-mediated restriction point (R) and nutrient-mediated proposed Cell Growth 
Checkpoint, and also based on my preliminary findings that various cancer cells exhibit complex 
cell cycle arrest pattern upon glutamine deprivation as evidenced by FACS profile, major questions 
that we sought to address were (i) Is there a distinct G1 checkpoint mediated by amino acids 
different from GF-dependent R and mTOR-mediated cell growth checkpoint? (ii) Are there novel S- 
and G2/M phase checkpoints mediated by glutamine?  Using several approaches detailed in Chapter 
2, we show that GF-mediated R, amino acid-mediated checkpoints, and mTOR-mediated late-G1 
checkpoint are indeed distinct and distinguishable.  Importantly, we also show that amino acid 
sensing is dysregulated in some cancer cells, whereby they arrest in S- and G2/M-phase of the cell 
cycle. 
In chapter 3, we identify that K-Ras mutation is required for overriding the amino-acid 
mediated G1 cell cycle arrest.  We also show that this aberrant response to amino acid deprivation 
could create synthetic lethality to phase-specific cytotoxic drugs and prove to be an Achilles heel in 
K-Ras mutant cancer cells. 
 
The work described here raises a few interesting questions: 
(i) What is the mechanism through which nutrient amino acid deprivation mediates G1 
arrest in non-transformed cells?  From our data in cancer cells, where rapamycin/Torin1 
cause G1 arrest but amino acid deprivation does not, the G1 arrest upon amino acid 
deprivation is likely independent of mTOR pathway or perhaps there are other pathways 
involved in addition to the mTOR pathway to mediate the arrest.  K-Ras mutant cancer 
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cells override the amino acid-mediated G1 checkpoint, indicating that cross-talk and 
compensation between the K-Ras/MAPK and PI3K/mTOR pathway is involved in 
mediating G1 cell cycle arrest. 
(ii) Are there novel S- and G2/M-phase checkpoints?  With the cell cycle freeze in BJ cells 
upon amino acid deprivation and non-G1 arrest in cancer cells, it is evident that there is 
additional amino acid sensing in S- and G2/M-phase of the cell cycle.  The need and the 
mechanism for amino acid sensing warrants further investigation. 
(iii)It has been suggested that glutamine favors proliferation by replenishing citric acid cycle 
intermediates.  However, other important functions of glutamine in intermediary 
metabolism – such as in nucleotide biosynthesis and participating in overall nitrogen 
balance – remain largely ignored.  It is also likely that glutamine plays different roles in 
different phases of the cell cycle. 
 
Given the extensive metabolic deregulation in cancer, exploiting the metabolic vulnerabilities could 
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